^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    clonoSEQ®

    Company:
    Adaptive Biotech
    2d
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital | Initiation date: Apr 2026 --> Aug 2026
    Trial initiation date
    |
    clonoSEQ®
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    2d
    A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: May 2026 --> Nov 2026
    Trial initiation date
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    Revuforj (revumenib)
    7d
    Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=30, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ABL1 (ABL proto-oncogene 1) • EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
    |
    ABL1 T315I
    |
    clonoSEQ®
    |
    Scemblix (asciminib)
    8d
    Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. (PubMed, Am J Hematol)
    This multitargeted regimen addresses the biologic heterogeneity of MCL and permits flexible MRD-guided decisions on consolidation and maintenance. Trial Registration: ClinicalTrials.gov identifier: NCT04626791.
    Journal
    |
    clonoSEQ®
    |
    Rituxan (rituximab) • cytarabine • bortezomib • Calquence (acalabrutinib)
    9d
    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL (clinicaltrials.gov)
    P3, N=466, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    15d
    Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (clinicaltrials.gov)
    P1, N=52, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    clonoSEQ®
    |
    Carvykti (ciltacabtagene autoleucel) • Hyleukin-7 (efineptakin alfa)
    16d
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9
    Enrollment closed • Enrollment change
    |
    clonoSEQ®
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    16d
    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    22d
    Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=720, Not yet recruiting, Dana-Farber Cancer Institute
    New P3 trial
    |
    TP53 (Tumor protein P53)
    |
    clonoSEQ®
    |
    bortezomib • dexamethasone • iberdomide (CC-220) • Lynozyfic (linvoseltamab-gcpt) • Sarclisa subcutaneous (isatuximab subcutaneous) • captisol-enabled melphalan
    24d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Oct 2026 --> Aug 2028 | Trial primary completion date: Apr 2026 --> Aug 2028
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ®
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    25d
    TrAVeRse: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=108, Active, not recruiting, AstraZeneca | Trial primary completion date: Jul 2028 --> Oct 2028 | Trial completion date: Jul 2028 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
    28d
    At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research (Adaptive Biotechnologies Press Release)
    "Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm."
    Clinical data
    |
    clonoSEQ®